Abbott has established the XIENCE Short DAPT program of clinical trials, which focuses on high risk bleeding patients. Shortening DAPT (Dual AntiPlatelet Therapy) duration may be particularly important for patients at higher risk of bleeding, e.g., older patients, patients taking anticoagulants, and patients with anemia or renal disease.
The studies in the XIENCE Short DAPT program are:
- The XIENCE 90 trial—examining 3 months (as short as 90 days) of DAPT
- The XIENCE 28 Global trial—examining 1 month (as short as 28 days) of DAPT
Dr. Mehran is global PI of both XIENCE 90 and XIENCE 28 Global Study. Dr. Marco Valgimigli is the PI of XIENCE 28 Global Study.
Currently, physicians have clinical society guidelines and scoring mechanisms to guide their decision when weighing their patients' needs and risk factors - their need for DAPT to reduce ischemic events after percutaneous coronary intervention (PCI)) and, for many patients, their bleeding risk while on prolonged DAPT. However, a definitive answer to the question of balancing patient benefits remains unknown.
“We have a lot of patients in whom DAPT cannot be longer than 1 [month] and we need to provide some answers to them.”
— MARCO VALGIMIGLI, MD
Find out more about both the XIENCE 90 and XIENCE 28 Global trials. You may also sign up to receive updates on the latest XIENCE study results as they become available.
AP2945225-WBU Rev. B
